JP2004534850A5 - - Google Patents

Download PDF

Info

Publication number
JP2004534850A5
JP2004534850A5 JP2003512363A JP2003512363A JP2004534850A5 JP 2004534850 A5 JP2004534850 A5 JP 2004534850A5 JP 2003512363 A JP2003512363 A JP 2003512363A JP 2003512363 A JP2003512363 A JP 2003512363A JP 2004534850 A5 JP2004534850 A5 JP 2004534850A5
Authority
JP
Japan
Prior art keywords
compound according
compound
phe
optionally substituted
phenylalanyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003512363A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004534850A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/021443 external-priority patent/WO2003006604A2/en
Publication of JP2004534850A publication Critical patent/JP2004534850A/ja
Publication of JP2004534850A5 publication Critical patent/JP2004534850A5/ja
Withdrawn legal-status Critical Current

Links

JP2003512363A 2001-07-12 2002-07-08 強力な選択的メラノコルチン−4受容体アゴニストとしての環状ペプチド Withdrawn JP2004534850A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30495801P 2001-07-12 2001-07-12
PCT/US2002/021443 WO2003006604A2 (en) 2001-07-12 2002-07-08 Cyclic peptides as potent and selective melanocortin-4 receptor agonists

Publications (2)

Publication Number Publication Date
JP2004534850A JP2004534850A (ja) 2004-11-18
JP2004534850A5 true JP2004534850A5 (enExample) 2005-12-22

Family

ID=23178678

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003512363A Withdrawn JP2004534850A (ja) 2001-07-12 2002-07-08 強力な選択的メラノコルチン−4受容体アゴニストとしての環状ペプチド

Country Status (5)

Country Link
US (1) US6960646B2 (enExample)
EP (1) EP1409521A2 (enExample)
JP (1) JP2004534850A (enExample)
CA (1) CA2453027A1 (enExample)
WO (1) WO2003006604A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
AU2002322466B2 (en) 2001-07-11 2007-08-30 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
MXPA05011830A (es) 2003-05-09 2006-01-26 Novo Nordisk As Peptidos para uso en el tratamiento de la obesidad.
EP1644023A2 (en) * 2003-06-19 2006-04-12 Eli Lilly And Company Melanocortin recptor 4(mc4) agonists and their uses
WO2005000338A1 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Uses of melanocortin-3 receptor (mc3r) agonist peptides
WO2005060985A1 (en) * 2003-12-10 2005-07-07 Merck & Co., Inc. Inhibition of voluntary ethanol consumption with selective melanocortin 4-receptor agonists
JP2007530674A (ja) * 2004-03-29 2007-11-01 イーライ リリー アンド カンパニー 連続注入によって投与されるメラノコルチン−4受容体(mc4r)アゴニストペプチドの使用
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
WO2006129317A1 (en) * 2005-05-31 2006-12-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem BACKBONE CYCLIZED MELANOCORTIN STIMULATING HORMONE (α S ) ANALOGS
US20070021433A1 (en) 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP5628796B2 (ja) 2008-06-09 2014-11-19 パラティン テクノロジーズ, インコーポレイテッドPalatin Technologies, Inc. 性的不能の治療用のメラノコルチンレセプタ特異的ペプチド
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
WO2010144344A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Melanocortin receptor-specific peptides
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
AU2010321738B2 (en) * 2009-11-23 2016-07-14 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
EA201290295A1 (ru) 2009-11-23 2013-01-30 Палатин Текнолоджиз, Инк. Специфичные к рецептору меланокортина-1 линейные пептиды
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2826649C (en) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
BR112015019836A2 (pt) 2013-02-22 2017-07-18 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de um composto
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US10899793B2 (en) 2016-05-27 2021-01-26 Regents Of The University Of Minnesota Melanocortin ligands and methods of use thereof
US11124541B2 (en) 2016-10-18 2021-09-21 Regents Of The University Of Minnesota Chimeric melanocortin ligands and methods of use thereof
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
US11332499B2 (en) 2018-08-16 2022-05-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622860A (en) * 1994-02-17 1997-04-22 The Regents Of The University Of Michigan Genes encoding melanocortin receptors
US6054556A (en) * 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
CA2251520C (en) * 1997-10-31 2003-12-30 Honda Giken Kogyo Kabushiki Kaisha Pipe connector connection checking assembly
WO2002018437A2 (en) 2000-08-30 2002-03-07 F. Hoffmann-La Roche Ag Cyclic peptides having melanocortin-4 receptor agonist activity

Similar Documents

Publication Publication Date Title
JP2004534850A5 (enExample)
JP2021100937A5 (enExample)
JP2013507439A5 (enExample)
MY136034A (en) New medicaments for the treatment of chronic obstructive pulmonary disease
JP2020097577A5 (enExample)
JP2007145875A5 (enExample)
JP2005537234A5 (enExample)
JP2005500357A5 (enExample)
CY1115719T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
EP2573079A3 (en) Benzimidazole quinolinones and uses thereof
NZ522326A (en) Adenosine A2A receptor antagonists
JP2006182786A5 (enExample)
JP2011528713A5 (enExample)
JP2009535352A5 (enExample)
EP2036902A3 (en) Urea compounds active as vanilloid receptor antagonist for the treatment of pain
MXPA04001500A (es) Compuestos que tienen un efecto sobre la glucocinasa.
JP2006514012A5 (enExample)
JP2019515908A5 (enExample)
JP2008513510A5 (enExample)
JP2004502755A5 (enExample)
JP2006514116A5 (enExample)
JP2010500284A5 (enExample)
JP2010539091A5 (enExample)
TW200531688A (en) Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
JP2012523416A5 (enExample)